TOBREX (tobramycin) by Novartis. Approved for aminoglycoside antibacterial [epc]. First approved in 1984.
Drug data last refreshed 3d ago
Aminoglycoside Antibacterial
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Tobramycin Injection to Prevent Infection in Open Fractures
Safety and Efficacy in Patients Treated for Hip or Knee PJI With Vancomycin and Tobramycin Joint Irrigation
SPI-1005 for Prevention and Treatment of Tobramycin Induced Ototoxicity
Dose-finding Study to Assess the Efficacy, Safety and Tolerability of Tobramycin Inhalation Powder in Patients With Non-Cystic Fibrosis Bronchiectasis and Pulmonary P. Aeruginosa Infection
Addition of Tobramycin Inhalation in the Treatment of Ventilator Associated Pneumonia
Worked on TOBREX at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo